DBV Technologies shares drop after reporting high FY operating expenses

DBV Technologies SA

04/05/2026 08:43

** Shares in DBV Technologies DBV.PA fall 4.5% after the French biopharmaceutical company reported a high level of operating expenses for full-year 2025

** The company's operating income rose to $5.6 million, while R&D expenses increased to $27.3 million

** Portzamparc says it is "surprised by such a high level of operating expenses and the rise in R&D costs"

** The broker also says it will monitor cash burn, noting that it is likely to accelerate with the upcoming launch of the THRIVE trial in infants aged 6 to 12 months for peanut allergy treatment

** If losses hold, the shares are on track for a worst day since April 15

 (Reporting by Lucie Barbier)

 ((Email: lucie.barbier@thomsonreuters.com))